Zobrazeno 1 - 10
of 49
pro vyhledávání: '"K. Benwell"'
Publikováno v:
BioTechniques, Vol 23, Iss 3, Pp 402-407 (1997)
Externí odkaz:
https://doaj.org/article/0c83740917ed4b0ca9d481c760e1e89b
Publikováno v:
Journal of Cellular and Molecular Medicine
The dual‐specificity tyrosine‐regulated kinases DYRK1A and DYRK1B play a key role in controlling the quiescence‐proliferation switch in cancer cells. Serum reduction of U87MG 2D cultures or multi‐cellular tumour spheroids induced a quiescent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f43e2d1ac074923f3c78a3b89f027a0
https://doi.org/10.1111/jcmm.17002
https://doi.org/10.1111/jcmm.17002
Autor:
András Kotschy, Allan E. Surgenor, Andrea Fiumana, James Brooke Murray, Andrew Massey, Thomas Edmonds, Nicolas Foloppe, Didier Demarles, Pawel Dokurno, Mike Burbridge, Francisco Cruzalegui, K Benwell, Roderick E. Hubbard, Stuart C. Ray, Walmsley David, Julia Smith
Publikováno v:
Journal of Medicinal Chemistry. 64:8971-8991
The serine/threonine kinase DYRK1A has been implicated in regulation of a variety of cellular processes associated with cancer progression, including cell cycle control, DNA damage repair, protection from apoptosis, cell differentiation, and metastas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aa669f3368474f2d06cdec15c347340
https://doi.org/10.1021/acs.jmedchem.1c00024
https://doi.org/10.1021/acs.jmedchem.1c00024
Autor:
Attila Paczal, Thomas Edmonds, Nicolas Foloppe, Andrew Massey, András Kotschy, Mike Burbridge, Francisco Cruzalegui, Pawel Dokurno, Didier Demarles, Roderick E. Hubbard, Csaba Wéber, Sipos Melinda, Balázs Bálint, Vilibald Kun, K Benwell, James Murray, Walmsley David, Alain Bruno
Publikováno v:
Journal of medicinal chemistry. 64(10)
The kinase DYRK1A is an attractive target for drug discovery programs due to its implication in multiple diseases. Through a fragment screen, we identified a simple biaryl compound that is bound to the DYRK1A ATP site with very high efficiency, altho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a128ac92882fb9193bbec98b205ee8c0
https://pubmed.ncbi.nlm.nih.gov/33975430
https://pubmed.ncbi.nlm.nih.gov/33975430
Autor:
David R. Lee, Risa K. Benwell
Publikováno v:
Clinical Immunology. 134:178-187
Requirements for human Th17 differentiation in the context of activated dendritic cells (DCs) are still emerging. Here, we demonstrate that several Toll-like receptor (TLR) ligands, particularly LPS and a synthetic lipoprotein, activate human DCs to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b22e1b904f0acde4bd00711202b15a14
https://doi.org/10.1016/j.clim.2009.09.013
https://doi.org/10.1016/j.clim.2009.09.013
Autor:
Sean McKenna, Andrew Massey, Lisa Baker, K Benwell, Heather Simmonite, Teresa Brooks, Michael Wood, Stephen Stokes, Nicolas Foloppe, Andrea Fiumana, Paul Webb, Stefaniak Emma Jayne, Christopher J. Northfield, Macias Alba, Zoe Daniels, Daniel Maddox, Helen Browne, Joanne Wayne, Christopher John Graham, Stuart C. Ray
Publikováno v:
Molecular Cancer Therapeutics. 17:B163-B163
On sustaining damage to their DNA, cells employ a sophisticated mechanism of detection and repair, termed the DNA damage response (DDR). As a critical component of the DDR and G2/M checkpoint, Chk1 kinase represents an attractive target for cancer th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4ad7ce30c29670a74658952948678e4
https://doi.org/10.1158/1535-7163.targ-17-b163
https://doi.org/10.1158/1535-7163.targ-17-b163
Publikováno v:
Cellular Immunology. 264:119-126
To better understand the relative efficiencies of using different TLR ligand-activated DCs to induce human CD4(+) T lymphocyte responses, human DCs were activated with two viral and two bacterial TLR ligands, and their production of IL12, TNFalpha, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c2d2f46f087fcb7c91ae4a2d4a6c348
https://doi.org/10.1016/j.cellimm.2010.05.008
https://doi.org/10.1016/j.cellimm.2010.05.008
Autor:
Sarah Dugdale, Ian Yule, Anthony R Knight, Chen I-Jen, Tim Haymes, Sean Lightowler, Heather Simmonite, Mike Comer, Anthony Padfield, Teresa Brooks, Allan M. Jordan, A Misra, Guy A. Kennett, Angela Merrett, Simon Bedford, K Benwell, Melanie Wong, Karine G. Poullennec, Loic LeStrat, Mark Reece, Burkhard Klenke
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:5945-5949
We herein report the discovery of a novel class of antagonists of the human adenosine A2B receptor. This low molecular weight scaffold has been optimized to offer derivatives with potential utility for the alleviation of conditions associated with th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cca22fbb50c8948de07dce59be48f66
https://doi.org/10.1016/j.bmcl.2009.08.040
https://doi.org/10.1016/j.bmcl.2009.08.040
Autor:
Nathaniel J. T. Monck, A Misra, K Benwell, Teresa Brooks, Antony R. Knight, Nicolas Foloppe, Guy A. Kennett
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:4183-4190
Ligand-based virtual screening with a 3D pharmacophore led to the discovery of 30 novel, diverse and drug-like ligands of the human cannabinoid receptor 1 (hCB(1)). The pharmacophore was validated with a hit rate of 16%, binding selectivity versus hC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78742d20c950f66388c9a544e566cbed
https://doi.org/10.1016/j.bmcl.2009.05.114
https://doi.org/10.1016/j.bmcl.2009.05.114
Autor:
David R. Adams, Suneel Gaur, Simon E. Ward, A Misra, Allan Fletcher, Claire Elizabeth Dawson, Porter Richard Hugh Phillip, Anthony Lawrence, P R Giles, Ian Anthony Cliffe, Lars J. S. Knutsen, Colin T. Dourish, Scott Murray Weiss, Roger John Gillespie, Antony R. Knight, Allan M. Jordan, Robert M. Pratt, K Benwell, Douglas S. Williamson, Joanne Lerpiniere, Robin Shepherd, David Bebbington, Rebecca Upton
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:2916-2919
The (-)-(11R,2'S)-enantiomer of the antimalarial drug mefloquine has been found to be a reasonably potent and moderately selective adenosine A(2A) receptor antagonist. Further investigation of this compound has led to the discovery of a series of ket
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::400b9a1d75c6350027c97a4f91d5a4dc
https://doi.org/10.1016/j.bmcl.2008.03.075
https://doi.org/10.1016/j.bmcl.2008.03.075